


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on June 11, 2009.



Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Patent Application
Docket No. BKR.110T

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Xiaozhen Xie, Ph.D.
Art Unit : 1646
Applicants : Michel Christian Morre, Brigitte Assouline, Pierre Cortez, Anne Gregoire
Serial No. : 10/522,883
Filed : April 18, 2005
Conf. No. : 9491
For : IL-7 Drug Substance, Composition, Preparation and Uses

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98


Sir:

In accordance with 37 CFR §1.56, the reference listed on the attached form PTO/SB/08 is being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Applicants have not submitted a copy of the published U.S. Patent Application cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

It is respectfully requested that the reference cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that its consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachment: Form PTO/SB/08